caa a22 4500 465761933 CHVBK 20180323111901.0 cr unu---uuuuu 170327e19901201xx s 000 0 eng 10.1007/BF02987099 doi (NATIONALLICENCE)springer-10.1007/BF02987099 Deoxyribonucleoside triphosphate pools and ara-ctp levels in P388 murine leukemic cells treated with 1-B-D-Arabinofuranosylcytosine-5′ -stearylphosphate which is a newly synthesized derivative OF 1-B-D-arabinofuranosylcytosine [Elektronische Daten] [Masamune Higashigawa, Hiroki Hori, Toshiki Ohkubo, Hajime Kawasaki, Tamotu Yoshizumi, Minoru Sakurai] 1-B-D-arabinofuranosylcytosine-573′-stearylphosphate (C18PCA), which is an Ara-CMP ester and one of the most promising orally effective anti-leukemic drugs, is a newly synthesized derivative of Ara-C. The antitumor effect of C18PCA and Ara-C was investigated against the P388 ascites tumor in BDF1 mice. Treatment with C18PCA (100 mg kg-1, orally) and Ara-C (40 mg kg-1, subcutaneously) was administered on days 1, 3 and 5 after tumor inoculation. The percentage increase in lifespans of the mice treated with C18PCA or Ara-C were 84.4% and 53.9%, respectively. The determination of the plasma Ara-C concentration revealed that the plasma concentration of Ara-C was retained much longer in mice which orally received C18PCA than in those which received Ara-C. By using high-performance liquid chromatography, it was revealed that the deoxyribonucleo-side triphosphate pools increased gradually but Ara-CTP concentration once increased, then decreased rapidly when Ara-C was administered subcutaneously. On the other hand, both the intracellular deoxyribonucleoside triphosphate (dNTP) pools and Ara-CTP level increased gradually after oral administration of C18PCA. We concluded that these longer-term biochemical effects, even if the plasma concentration of Ara-C and Ara-CTP level were low, might be correlated with antitumor effects of C18PCA. Humana Press Inc., 1990 1-B-Darabinofuranosyl cytosine-5′-stearylphosphate (C18PCA) nationallicence Ara-C nationallicence Ara-CTP nationallicence dNTP nationallicence Higashigawa Masamune Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Hori Hiroki Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Ohkubo Toshiki Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Kawasaki Hajime Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Yoshizumi Tamotu Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Sakurai Minoru Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 223-226 0736-0118 7:4<223 1990 7 12032 https://doi.org/10.1007/BF02987099 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02987099 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Higashigawa Masamune Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 700 1- Hori Hiroki Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 700 1- Ohkubo Toshiki Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 700 1- Kawasaki Hajime Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 700 1- Yoshizumi Tamotu Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 700 1- Sakurai Minoru Department of Pediatrics, Mie University School of Medicine, 2-174, Edobashi, Tsucity, 514, Mieken, Japan aut NATIONALLICENCE 773 0- Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 223-226 0736-0118 7:4<223 1990 7 12032 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer